Reata Pharmaceuticals Ownership
| RETADelisted Stock | USD 172.36 0.02 0.01% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Reata |
Reata Stock Ownership Analysis
About 88.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 2.62. Reata Pharmaceuticals had not issued any dividends in recent years. Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas. Reata Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 346 people. To find out more about Reata Pharmaceuticals contact Warren Huff at 972 865 2219 or learn more at https://www.reatapharma.com.Reata Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Reata Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Reata Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Reata Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Michael Wortley over six months ago Disposition of 49701 shares by Michael Wortley of Reata Pharmaceuticals subject to Rule 16b-3 | ||
Michael Wortley over six months ago Sale by Michael Wortley of 807 shares of Reata Pharmaceuticals | ||
Michael Wortley over six months ago Acquisition by Michael Wortley of 4125 shares of Reata Pharmaceuticals subject to Rule 16b-3 | ||
Michael Wortley over six months ago Sale by Michael Wortley of 894 shares of Reata Pharmaceuticals | ||
Michael Wortley over a year ago Sale by Michael Wortley of 414 shares of Reata Pharmaceuticals | ||
Michael Wortley over a year ago Acquisition by Michael Wortley of 63650 shares of Reata Pharmaceuticals subject to Rule 16b-3 |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Reata Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Reata Pharmaceuticals' short interest history, or implied volatility extrapolated from Reata Pharmaceuticals options trading.
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Other Consideration for investing in Reata Stock
If you are still planning to invest in Reata Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reata Pharmaceuticals' history and understand the potential risks before investing.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |